View Older Stories View More Recent Stories

Jul 24, 2023 09:00AM Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
Jul 10, 2023 07:00AM Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Jul 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2023 07:00AM Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 25, 2023 07:01AM Apellis Pharmaceuticals (APLS) Phase 2 MERIDIAN Study in ALS Did Not Meet Primary Endpoint
May 25, 2023 07:00AM Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 5, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023 04:05PM Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 3, 2023 07:00AM Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
Apr 27, 2023 07:00AM Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
Apr 27, 2023 07:00AM Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
Apr 24, 2023 05:30AM Apellis Pharmaceuticals (APLS) Presents Phase 3 Functional Analyses of SYFOVRE
Apr 23, 2023 06:05PM Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
Apr 23, 2023 06:05PM Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
Apr 21, 2023 07:02AM Apellis Pharmaceuticals (APLS) Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Apr 21, 2023 07:00AM Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Apr 21, 2023 07:00AM Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Apr 17, 2023 07:00AM Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
Apr 17, 2023 07:00AM Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
Apr 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2023 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 1, 2023 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 21, 2023 04:13PM Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 21, 2023 04:13PM Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 17, 2023 04:06PM FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Feb 17, 2023 04:06PM FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Feb 13, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 13, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 6, 2023 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 5, 2023 07:05AM Apellis Pharmaceuticals (APLS) Appoints Caroline Baumal as Chief Medical Officer
Jan 5, 2023 07:00AM Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
Jan 5, 2023 07:00AM Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
Jan 3, 2023 07:00AM Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 07:00AM Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 16, 2022 07:02AM Apellis Pharmaceuticals (APLS) Submits EU Marketing Authorization Application for Pegcetacoplan
Dec 16, 2022 07:00AM Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
Dec 16, 2022 07:00AM Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
Dec 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 22, 2022 04:05PM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 22, 2022 04:05PM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 18, 2022 07:01AM Apellis Pharmaceuticals (APLS) Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023
Nov 18, 2022 07:00AM Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
Nov 18, 2022 07:00AM Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
Nov 7, 2022 04:05PM Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
View More Recent Stories View Older Stories